CROSSROADS STRATEGIES, LLC for MERCK & CO., INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Taxation/Internal Revenue Code TAX
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, drug pricing, and the importation of biopharmaceuticals. Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). Vaccine provisions and TRICARE Pilot Program in S.1790/H.R.2500, National Defense Authorization Act for Fiscal Year 2020 (P.L.116-92). S.1895, Lower Health Care Costs Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing. Proposed Part B IPI Demonstration Project. S.551, REFUND Act of 2019. H.R.107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs. H.R.3, Lower Drug Costs Now Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Budget/Appropriations BUD
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure; H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and H.R.2740, the FY2020 Consolidated measure; H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94); Reimbursement and vial size issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Trade (domestic/foreign) TRD
Issues related to international trade including the United States-Mexico-Canada Agreement (USMCA).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| KATHERINE DAPPER | — |
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.